Insider · CIK 0001999390
George Magrath
Files at IRD (Ocuphire Pharma, Inc.). First filing Nov 19, 2024, latest Jul 27, 2026.
In brief
George Magrath files SEC Form 4 as CEO and director at IRD (Ocuphire Pharma, Inc.). Since Nov 19, 2024, George Magrath has reported 2 open-market buys worth $199k and 3 open-market sells worth $205k, the latest filed on Jul 27, 2026.
A track record needs three past buys with six months of prices behind them; George Magrath has 2, so none is measured yet.
The newest scored trade: sold $28k of IRD on Jul 23, 2026, filed Jul 27, 2026, scored 45 (moderate). In the last 12 months: 0 buys worth $0 and 3 sells worth $205k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IRD: Ocuphire Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Ocuphire Pharma, Inc. | $28k 9,475 shares | -1% | +175% from low-49% from high | |
| 47Moderate | Ocuphire Pharma, Inc. | $50k 9,511 shares | -1% | +586% from low-9% from high | |
| 51Moderate | Ocuphire Pharma, Inc. | $127k 24,438 shares | -1% | +631% from low0% from high | |
| 46Moderate | IRDbuy Ocuphire Pharma, Inc. | $98k 100,000 shares | +20% | - | |
| 49Moderate | Ocuphire Pharma, Inc. | $101k 100,000 shares | +25% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 23, 2026 | IRD Opus Genetics, Inc. | 9,475 0.01% of outstanding | $29k | Jul 23, 2026 | $50k |
| Apr 23, 2026 | IRD Opus Genetics, Inc. | 9,511 0.01% of outstanding | $127k | Apr 23, 2026 | $127k |
| Mar 16, 2026 | IRD Opus Genetics, Inc. | 24,438 0.04% of outstanding | $127k | Mar 16, 2026 | none |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | IRD Ocuphire Pharma, Inc. | MOption exercise Common Stock | +392,157 | $1.15 | $451k | 2,124,026 | 32 d ago |
| Sep 9, 2026 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -75,541 | $5.97 | $451k | 2,048,485 | 32 d ago |
| Sep 9, 2026 | IRD Ocuphire Pharma, Inc. | MOption exercise Warrant (right to buy)derivative | -392,157 | $0.00 | $0 | 0 | 32 d ago |
| Jul 23, 2026 | IRD Ocuphire Pharma, Inc. | SOpen-market sale Common Stock | -9,475 | $2.95 | $28k | 1,731,869 | Jul 27, 2026 |
| Apr 23, 2026 | IRD Ocuphire Pharma, Inc. | SOpen-market sale Common Stock | -9,511 | $5.22 | $50k | 1,741,344 | Apr 27, 2026 |
| Mar 16, 2026 | IRD Ocuphire Pharma, Inc. | SOpen-market sale Common Stock | -24,438 | $5.21 | $127k | 1,750,855 | Mar 18, 2026 |
| Jan 22, 2026 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +483,639 | $0.00 | $0 | 1,775,293 | Jan 26, 2026 |
| Nov 1, 2025 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -30,350 | $2.30 | $70k | 1,291,654 | Nov 5, 2025 |
| Nov 1, 2025 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -30,350 | $2.30 | $70k | 1,291,654 | Nov 4, 2025 |
| Dec 26, 2024 | IRD Ocuphire Pharma, Inc. | POpen-market purchase Common Stock | +100,000 | $0.98 | $98k | 599,150 | Dec 30, 2024 |
| Dec 23, 2024 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +6,200 | $0.00 | $0 | 499,150 | Dec 23, 2024 |
| Nov 15, 2024 | IRD Ocuphire Pharma, Inc. | POpen-market purchase Common Stock | +90,294 | $1.01 | $91k | 483,244 | Nov 19, 2024 |
| Nov 18, 2024 | IRD Ocuphire Pharma, Inc. | POpen-market purchase Common Stock | +9,706 | $1.02 | $9,943 | 492,950 | Nov 19, 2024 |
| Nov 1, 2024 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -37,050 | $1.18 | $44k | 392,950 | Nov 5, 2024 |
| Nov 1, 2023 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +400,000 | $0.00 | $0 | 400,000 | Nov 3, 2023 |
| Nov 1, 2023 | IRD Ocuphire Pharma, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Nov 3, 2023 |
Questions about George Magrath
Answered from the filings on this page, as of the latest one.
Is George Magrath buying or selling?
In the last 12 months George Magrath reported 0 open-market buys worth $0 and 3 open-market sells worth $205k on SEC Form 4; the latest was sold $28k of IRD on Jul 23, 2026. Grants, option exercises and tax withholding are not counted.
How did George Magrath's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and George Magrath has 2.
Where does George Magrath file Form 4?
George Magrath has filed Form 4 at IRD (Ocuphire Pharma, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.